CLB vs RES

For growth investors, RPC, Inc.

(RES) is the stronger pick with 15. 0% revenue growth year-over-year, versus 0. 5% for Core Laboratories N. V. (CLB). Core Laboratories N. V. (CLB) offers the better valuation at 18. 7x trailing P/E (21. 2x forward), making it the more compelling value choice. Analysts rate Core Laboratories N. V. (CLB) a "Hold" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Core Laboratories N.

V. (CLB) is the cheapest at 18. 7x versus RPC, Inc. at 45. 9x. On forward P/E, Core Laboratories N. V. is actually cheaper at 21. 2x.

Over the past 5 years, RPC, Inc.

(RES) delivered a total return of +23. 4%, compared to -71. 5% for Core Laboratories N. V. (CLB). Over 10 years, the gap is even starker: RES returned -45. 9% versus CLB's -83. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), RPC, Inc.

(RES) is the lower-risk stock at 0. 35β versus Core Laboratories N. V. 's 0. 96β — meaning CLB is approximately 174% more volatile than RES relative to the S&P 500. On balance sheet safety, RPC, Inc. (RES) carries a lower debt/equity ratio of 9% versus 74% for Core Laboratories N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), RPC, Inc.

(RES) is pulling ahead at 15. 0% versus 0. 5% for Core Laboratories N. V. (CLB). On earnings-per-share growth, the picture is similar: Core Laboratories N. V. grew EPS 3. 0% year-over-year, compared to -65. 1% for RPC, Inc.. Over a 3-year CAGR, CLB leads at 2. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Core Laboratories N.

V. (CLB) is the more profitable company, earning 6. 0% net margin versus 2. 0% for RPC, Inc. — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CLB leads at 9. 3% versus 3. 5% for RES. At the gross margin level — before operating expenses — CLB leads at 17. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Core Laboratories N.

V. (CLB) trades at 21. 2x forward P/E versus 35. 5x for RPC, Inc. — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLB: 96. 5% to $25. 00.

All stocks in this comparison pay dividends.

RPC, Inc. (RES) offers the highest yield at 2. 3%, versus 0. 3% for Core Laboratories N. V. (CLB).

For long-horizon retirement investors, RPC, Inc.

(RES) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), 2. 3% yield). Both have compounded well over 10 years (RES: -45. 9%, CLB: -83. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Energy sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RES pays a dividend while CLB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.